These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21179186)

  • 1. HIV infection and aging.
    Blanco JR; Caro AM; Pérez-Cachafeiro S; Gutiérrez F; Iribarren JA; González-García J; Ferrando-Martínez S; Navarro G; Moreno S
    AIDS Rev; 2010; 12(4):218-30. PubMed ID: 21179186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV infection in older patients in the HAART era.
    Grabar S; Weiss L; Costagliola D
    J Antimicrob Chemother; 2006 Jan; 57(1):4-7. PubMed ID: 16284223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
    Manfredi R
    Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspective on HIV infection and aging: emerging research on the horizon.
    Casau NC
    Clin Infect Dis; 2005 Sep; 41(6):855-63. PubMed ID: 16107986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
    Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact on weight and height with the use of HAART in HIV-infected children.
    Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
    Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children.
    Spiegel HM; Chandwani R; Sheehy ME; Dobroszycki J; Fennelly G; Wiznia A; Radding J; Rigaud M; Pollack H; Borkowsky W; Rosenberg M; Nixon DF
    J Infect Dis; 2000 Jul; 182(1):88-95. PubMed ID: 10882585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus in an aging population, a complication of success.
    Kirk JB; Goetz MB
    J Am Geriatr Soc; 2009 Nov; 57(11):2129-38. PubMed ID: 19793157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the prevalence of distal symmetrical polyneuropathy and its risk factors among HAART-treated and untreated HIV infected individuals.
    Shurie JS; Deribew A
    Ethiop Med J; 2010 Apr; 48(2):85-93. PubMed ID: 20608012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.